Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Compound amino acid (19) + alanyl-glutamine is a specialized parenteral nutrition formulation developed by the Institute of Radiation and Radiation Medicine at the Academy of Military Medical Sciences in China. It consists of a balanced mixture of 19 essential and non-essential amino acids (specifically the 19AA-I formulation) supplemented with the stable dipeptide alanyl-glutamine. This combination is designed to provide a high-quality nitrogen source for patients in severe catabolic states, such as those following major trauma, surgery, or burns. Alanyl-glutamine serves as a stable precursor to L-glutamine, an amino acid that becomes conditionally essential during critical illness to support the immune system, maintain intestinal mucosal integrity, and preserve muscle mass. The product is administered intravenously to maintain nitrogen balance and promote recovery in patients who cannot receive adequate enteral nutrition.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on compound amino acid (19) + alanyl-glutamine.